Area of research
Molecular Biology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Gene expression and cancer classification, Bioinformatics and Genomic Networks, Radiomics and Machine Learning in Medical Imaging, and Cancer Genomics and Diagnostics.
Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer-Related Lymphedema.
Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery.
Clinicogenomic Characterization of Primary Sclerosing Cholangitis-Associated Biliary Tract Cancers.
Figure 1 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Table 5 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Table 1 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Table 3 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Table 2 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Figure 2 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Supplementary Table 1 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Table 4 from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
Data from Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
The Hallmarks of Predictive Oncology
Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis.
Protein–ligand data at scale to support machine learning
The Hallmarks of Predictive Oncology.
CD103+CD56+ ILCs Are Associated with an Altered CD8+ T-cell Profile within the Tumor Microenvironment.
Health Data Nexus: an open data platform for AI research and education in medicine.
Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors.
Supplementary Table S3 from CD103<sup>+</sup>CD56<sup>+</sup> ILCs Are Associated with an Altered CD8<sup>+</sup> T-cell Profile within the Tumor Microenvironment
Supplementary Figure S10 from CD103<sup>+</sup>CD56<sup>+</sup> ILCs Are Associated with an Altered CD8<sup>+</sup> T-cell Profile within the Tumor Microenvironment
Supplementary Table 12 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 14 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Methods S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Supplementary Table 6 from CD103<sup>+</sup>CD56<sup>+</sup> ILCs Are Associated with an Altered CD8<sup>+</sup> T-cell Profile within the Tumor Microenvironment
Supplementary Figure S1 from CD103<sup>+</sup>CD56<sup>+</sup> ILCs Are Associated with an Altered CD8<sup>+</sup> T-cell Profile within the Tumor Microenvironment
Supplementary Table 15 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 2 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Data from Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis
Supplementary Table S2 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.